FDA clears GE's PET/CT quantitative imaging technology
GE Healthcare has received FDA clearance of Q.Freeze, a PET/CT quantitative imaging technology designed for treatment evaluation earlier in a patient’s cancer treatment.

Q.Freeze combines the quantitative benefits of 4D phase-matched PET/CT imaging, MotionMatch, into one static image, according to the Waukesha, Wis.-based company. Q.Freeze is included in GE Healthcare's Q.Suite, a collection of features designed to provide consistent standardized uptake value (SUV) readings, and which does not have CE Mark approval.